MEDILOQ
OperatingMediloq, Inc.
Retail & Consumer · Boulder, CO · Founded 2021
Pioneered durable, ruggedized, child-safe containers for the b2c outdoor recreational market
Financials
FY2019–FY2023 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Principal holders% as the filing states it, Aug 16, 2022
- Daniel Estoque92.0%of company
Sold to the crowd
- Reg CF · Sep 202129,432 Class B Non-Voting Common Stock at $1.25$36.8K
- Reg CF · Dec 20228,553 shares at $2.37$20.3K· 17 investors
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
5 people
Dan is a gifted business visionary strategist with a tenacious, disciplined work ethic. He has a proven track record of conceiving, planning and executing projects during his 25 year career of helping entrepreneurs, startups and large corporations bring products to market. He has been involved in several startup ventures, and holds 6 revenue-generating patents. He works for the company 30 hours a week.
Dr. Kapasi is a health policy and governance strategy lead, currently working as UN strategy lead on the global COVID 19 task force. She is governance strategy lead and supply chain procurement head at Médecins Sans Frontières UN, advises the governments of 11 states on health policy, and studied at The Wharton School, Harvard Business School and NYU Stern School of Business. She works for the company 2 hours a week.
Ted Agne is a corporate communications executive in the areas of biotechnology, healthcare, and life sciences. He has served as an advisor and director for organizations including: Oxford Bioscience Network, One Nucleus, The Forsyth Institute biomedical research organization, the Global Federation of Competitiveness Councils, and Trifermed. He works for the company 2 hours a week.
Henry is a creative, high-energy, marketing professional with an entrepreneurial drive, and was responsible for creating and accelerating the company’s retail marketing strategy and brand recognition on a national level. His previous achievements include increasing revenue 10X for an entertainment business, and he spends countless hours volunteering. He works for the company 2 hours a week.
Nick has 12+ years as an accomplished sales leader with a passion for growing start-up brands. He is specialized in strategic development and implementation of short and long-term sales plans including product direction, consumer segmentation, market opportunities, growth expectations, and budget management. He works for the company 2 hours a week.
Names and titles as disclosed on SEC Form C, StartEngine. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
Filed 2 of 5 annual reports (FY2021–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
View all 10 filings on EDGAR- Form C-TRDec 23, 20240001858449-24-000003EDGAR
- Form C-ARApr 25, 20240001858449-24-000001EDGAR
- Form C-ARApr 27, 20230001858449-23-000001EDGAR
- Form CDec 5, 20220001665160-22-003020EDGAR
- Form C-USep 30, 20220001858449-22-000005EDGAR
- Form C/AAug 16, 20220001858449-22-000004EDGAR
- Form C/AJun 27, 20220001858449-22-000002EDGAR
- Form C/AMar 29, 20220001858449-22-000001EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.